Lytix Biopharma ASA (OB: LYTIX)
Health Care · Biotechnology · NO
Nkr8.00
-2.44% today · +7.0% 1Y
Lytix Biopharma ASA (OB: LYTIX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $65.15M and employs 14 people.
Over the last twelve months the share price has gained 7.0%, trading between 7.24 and 11.90.
Tweenvest scores Lytix Biopharma ASA across four factors: quality 37/100, value 53/100. Its strongest factor is value.
LYTIX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $65.15M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.34
- Dividend yield
- —
- Beta (5Y)
- -0.53
- 52-week high
- Nkr11.90
- 52-week low
- Nkr7.24
- Avg volume (3M)
- —
- Shares outstanding
- 76.90M
- Employees
- 14
- Next earnings
- —
About Lytix Biopharma ASA
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
- ISIN
- NO0010405780
- Founded
- 2003
- Listed since
- Jun 14, 2021
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MAIA Biotechnology, Inc.NYSEAM: MAIA | $66.91M | $1.10 | -9.84% |
| BIO-FD&C Co.,Ltd.KOSDAQ: A251120 | $66.79M | ₩10,240.00 | +1.19% |
| Curasight A/SNGM: CURAS | $66.59M | Dkr— | — |
| Bonus BioGroup Ltd.TASE: BONS | $66.29M | ₪0.18 | +2.92% |
| StemRIMTSE: 4599 | $65.11M | ¥164.00 | -6.29% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $64.85M | ₩1,949.00 | -16.71% |
| Spero Therapeutics, Inc.NasdaqGS: SPRO | $64.64M | $1.11 | -1.77% |
| XBiotech Inc.NasdaqGS: XBIT | $64.63M | $2.12 | -7.42% |
Figures last refreshed Oct 18, 2026.